Biotricity Inc
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux and Biocore Pro, an integrated ECG device and software that utilizes … Read more
Biotricity Inc (BTCY) - Net Assets
Latest net assets as of September 2025: $-31.66 Million USD
Based on the latest financial reports, Biotricity Inc (BTCY) has net assets worth $-31.66 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.32 Million) and total liabilities ($37.98 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-31.66 Million |
| % of Total Assets | -500.76% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 461.04 |
Biotricity Inc - Net Assets Trend (2014–2025)
This chart illustrates how Biotricity Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biotricity Inc (2014–2025)
The table below shows the annual net assets of Biotricity Inc from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $-30.01 Million | -0.12% |
| 2024-03-31 | $-29.98 Million | -51.05% |
| 2023-03-31 | $-19.85 Million | -825.31% |
| 2022-03-31 | $-2.14 Million | +68.61% |
| 2021-03-31 | $-6.83 Million | -127.74% |
| 2020-03-31 | $-3.00 Million | -68.78% |
| 2019-03-31 | $-1.78 Million | -1126.10% |
| 2018-03-31 | $173.25K | +103.95% |
| 2017-03-31 | $-4.38 Million | -253.85% |
| 2016-03-31 | $-1.24 Million | -464.46% |
| 2015-03-31 | $340.00K | -2.70% |
| 2014-03-31 | $349.44K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biotricity Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13926672400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $26.24K | % |
| Other Comprehensive Income | $145.79K | % |
| Other Components | $109.26 Million | % |
| Total Equity | $-30.01 Million | 100.00% |
Biotricity Inc Competitors by Market Cap
The table below lists competitors of Biotricity Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Webus International Limited Ordinary Shares
NASDAQ:WETO
|
$3.50 Million |
|
Norwegian Block Exchange AS
OL:NBX
|
$3.50 Million |
|
1ZX0
F:1ZX0
|
$3.50 Million |
|
TruCap Finance Limited
NSE:TRU
|
$3.50 Million |
|
BIRD RIVER RES. INC.
F:1Q1A
|
$3.50 Million |
|
POLARCOOL AB
F:98H
|
$3.49 Million |
|
Excel Realty N Infra Limited
NSE:EXCEL
|
$3.49 Million |
|
S&P GLOBAL (MHL.SG)
STU:MHL
|
$3.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biotricity Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -29,976,817 to -30,014,100, a change of -37,283.
- Net loss of 8,421,179 reduced equity.
- Dividend payments of 29,984 reduced retained earnings.
- New share issuances of 1,857,759 increased equity.
- Other comprehensive income increased equity by 113,414.
- Other factors increased equity by 6,442,707.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.42 Million | -28.06% |
| Dividends Paid | $29.98K | -0.1% |
| Share Issuances | $1.86 Million | +6.19% |
| Other Comprehensive Income | $113.41K | +0.38% |
| Other Changes | $6.44 Million | +21.47% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Biotricity Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-03-31 | $-0.11 | $0.25 | x |
| 2015-03-31 | $0.02 | $0.25 | x |
| 2016-03-31 | $-0.34 | $0.25 | x |
| 2017-03-31 | $-1.02 | $0.25 | x |
| 2018-03-31 | $0.03 | $0.25 | x |
| 2019-03-31 | $-0.32 | $0.25 | x |
| 2020-03-31 | $-0.50 | $0.25 | x |
| 2021-03-31 | $-1.09 | $0.25 | x |
| 2022-03-31 | $-0.28 | $0.25 | x |
| 2023-03-31 | $-2.29 | $0.25 | x |
| 2024-03-31 | $-3.33 | $0.25 | x |
| 2025-03-31 | $-1.39 | $0.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biotricity Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -61.07%
- • Asset Turnover: 2.44x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-456.72%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-74.02K |
| 2015 | -502.94% | 0.00% | 0.00x | 1.53x | $-1.74 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.06 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.37 Million |
| 2018 | -4977.71% | 0.00% | 0.00x | 5.36x | $-8.64 Million |
| 2019 | 0.00% | -2157.73% | 0.81x | 0.00x | $-8.41 Million |
| 2020 | 0.00% | -780.61% | 0.71x | 0.00x | $-10.77 Million |
| 2021 | 0.00% | -457.67% | 0.76x | 0.00x | $-14.81 Million |
| 2022 | 0.00% | -380.78% | 0.46x | 0.00x | $-28.92 Million |
| 2023 | 0.00% | -193.57% | 1.48x | 0.00x | $-16.67 Million |
| 2024 | 0.00% | -116.84% | 2.03x | 0.00x | $-11.10 Million |
| 2025 | 0.00% | -61.07% | 2.44x | 0.00x | $-5.42 Million |
Industry Comparison
This section compares Biotricity Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biotricity Inc (BTCY) | $-31.66 Million | 0.00% | N/A | $3.50 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |